Status:
COMPLETED
Metastatic or Refractory Soft Tissue Sarcomas and Metronomic Cyclophosphamide: Further Assessment of Efficacy and Safety
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Sarcoma
Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Brief Summary
Metronomic Cyclophosphamide's use in monotherapy as a palliative treatment against non-resectable and metastatic Soft Tissue Sarcomas relies on small retrospective cohorts' data. Current litterature ...
Eligibility Criteria
Inclusion
- patients over 18
- with inoperable or metastatic Soft Tissue Sarcoma
- treated with Metronomic Cyclophosphamide
- in 3 cancer care institutions located in 2 French regions (Bourgogne and Franche-Comté)
- between January 2005 and December 2021
Exclusion
- patients with bone, chondral sarcomas, desmoid, or gastrointestinal stromal tumors
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06216990
Start Date
January 1 2005
End Date
July 1 2022
Last Update
January 22 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.